KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

Description

Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.